Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms, Non-Small-Cell Lung
Conditions
Keywords
apatinib, T790 negative, NSCLC
Brief summary
This phase 2 study is designed to evaluate the safety and activity of apatinib,a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2, in combination with EGFR-TKI in NSCLC with T790M-negative after the failure of EGFR-TKI therapy.
Interventions
DRUGApatinib
Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
DRUGEGFR-TKI
Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Sichuan Cancer Hospital and Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed stage IIIB, IV non-squamous non-small cell lung cancer, with measurable lesions (the long axis of tumor lesions ≥ 10mm with CT, the short axis of lymph node lesions ≥ 15mm with CT, the lesions not receive radiotherapy, frozen or other local treatment); * Patients with slow progression on first-line EGFR TKI(erlotinib / icotinib / gefitinib) treatment; * No T790M mutation including an assessment from tumor biopsy obtained while on or subsequent to the most recent EGFR TKI therapy; * Eastern Cooperative Oncology Group (ECOG) performance status 0-2; * Life expectancy of more than 3 months; * Adequate bone marrow function: WBC ≥ 3.0 ×10 E+9/L, neutrophil ≥ 1.5 × 10 E+9/L, platelets ≥ 80 × 10E+9/L,Hb ≥ 10.0g/dL;a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL), a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤3UNL or ≤5UNL in case of liver metastasis, a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault); * Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug; * the participants volunteered to join this study should sign the informed consent forms, have better compliance in the follow-up;
Exclusion criteria
* Squamous cell carcinoma (including adenosquamous carcinoma); Small cell lung carcinoma (including small cell carcinoma and non-small cell mixed lung carcinoma); * Active brain metastases, cancerous meningitis, patients with spinal cord compression; * Rapid progression of the disease or cancer invades vital organs; * The distance between the tumor lesion and the large blood vessel is less than 5 mm, or there is a central tumor invading local macrovascular; * obvious pulmonary cavity or tumor necrosis; * Uncontrollable high blood pressure; * Grade Ⅱ or above myocardial ischemia or myocardial infarction or arrhythmia control is not good,Ⅲ \ Ⅳ grade cardiac insufficiency, or cardiac ultrasonography showed left ventricular ejection fraction (LVEF) \<50% according to the NYHA standard; * Have a history of interstitial lung disease or patients with interstitial lung disease; * Coagulation abnormalities (INR\> 1.5 or PT\> ULN + 4s or APTT\> 1.5 ULN) with bleeding tendency or undergoing thrombolytic or anticoagulant therapy; * There was significant hemoptysis within 2 months prior to enrollment, or a daily hemoptysis volume is 2.5 ml or above; * A clinically significant bleeding symptom or bleeding tendencies such as gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above, or vasculitis that occurred within 3 months prior to enrollment; * Aneurysm / venous thrombotic events such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; * Arterial / venous thrombotic events such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism within 12 months prior to enrollment; * Hereditary or acquired bleeding and thrombophilia, such as hemophilia, coagulopathy, thrombocytopenia, hypersplenism； * Long-term unhealed wounds or fractures; * Major surgery or severe traumatic injury, fracture or ulcer within 4 weeks prior to enrollment; * Unable to swallow, chronic diarrhea or intestinal obstruction; * Abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months prior to enrollment; * Urinary protein ≥ ++, 24-hour urinary protein ≥ 1.0 g; * Active infections require antimicrobial treatment; * ALK gene abnormalities (gene fusion or mutation occurred); * Pregnant or lactating women, or women unwilling or unable to take effective contraception;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | up to 24 months | the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | up to 36 months | The length of time from either the date of diagnosis or the start of treatment that half of the patients in a group of patients diagnosed with the disease are still alive. |
| Duration of response (DOR) | up to 24 months | From first response to the date of first documented disease progression |
| Disease Control Rate (DCR) | 24 weeks | the proportion of patients with a best overall response of CR, PR or SD in the whole body, as assessed per RECIST 1.1 by the investigator. |
| Overall response rate (ORR) | 24 weeks | the proportion of patients with a best overall confirmed response of CR or PR in the whole body as assessed per RECIST 1.1 by the investigator |
| the quality of life (QoL) | up to 36 months | Analysis of changes from baseline using the quality of life (QoL) instrument |
Countries
China
Contacts
Primary ContactJuan Li, MD
Backup ContactRui Shi, MD
Outcome results
None listed